NCT01776619View on ClinicalTrials.gov

Safety and Tolerability Study of Multiple Doses of PF-06305591

PHASE1CompletedINTERVENTIONAL

Enrollment

43

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Healthy

Interventions

DRUG

PF-06305591

14 day repeated 20mg BID doses

DRUG

Placebo

14 day repeated BID doses

DRUG

PF-06305591

14 day repeated 80mg BID doses

DRUG

Placebo

14 day repeated BID doses

DRUG

PF-06305591

14 day repeated 40mg BID doses

DRUG

Placebo

14 day repeated BID doses

DRUG

PF-06305591

14 day repeated BID doses

DRUG

PF-06305591

relative bioavailability tablet vs. solution and food effect at 50mg dose

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY